Navigation Links
Data for EntreMed's ENMD-2076 to Be Presented at the Upcoming AACR-NCI-EORTC Conference
Date:11/3/2009

yrosine kinase targets in addition to Aurora A kinase and other oncogenic proteins. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 targets a defined set of kinases, including Flt-3 and FGFR3, which have been shown to play important roles in the pathology of hematological cancers.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing primarily ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer. ENMD-2076 is currently in Phase 1 studies in advanced cancers, multiple myeloma, and leukemia. The Company's other therapeutic candidates include MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway currently in multiple Phase 2 clinical trials for cancer, and ENMD-1198, a novel antimitotic agent currently in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem® in rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securit
'/>"/>

SOURCE EntreMed
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. EntreMed Focuses on Development of ENMD-2076
2. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
3. Nautica Malibu Triathlon Presented by Toyota Raises $718,000 for Childrens Hospital Los Angeles Pediatric Cancer Research
4. Success of Shape-Up Somerville Childhood Obesity Intervention to be Presented at the Friedman School Symposium at Tufts, October 29-31, 2007 - Boston
5. Success of Shape Up Somerville childhood obesity intervention to be presented
6. Survival data presented from phase II study of hormone-resistant prostate cancer patients
7. Special Olympics Special Spirit in China Award Of Excellence Presented to Dedicated Friends of Special Olympics and City of Shanghai
8. UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring Clinical Study Results Presented at American Society for Dermatologic Surgery Annual Meeting
9. New Analyses of long-term LIALDA (mesalamine) data presented at ACG
10. Horizons AMI trial data to be presented at TCT 2007
11. AMIHOT II trial data presented at TCT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... 30, 2014 Daily Gossip reveals in its ... Him Desire You program, who shows a unique formula to ... of this method says that the program goes beyond mere ... Him Desire You review indicates that the program was created ... and his great techniques to make a man feel emotionally ...
(Date:8/30/2014)... 30, 2014 The term nutraceuticals ... Pharameuticals. Nutraceuticals is a source of healthy-dietary supplements ... natural food sources. Nutraceutical ingredients have certain curative ... human body. Nutraceutical health products include factors such ... and more. Although nature is the most bountiful ...
(Date:8/30/2014)... Tenn. (PRWEB) August 30, 2014 ... around the country for the past several years, ... Tennessee Hyperbaric Center have announced a scholarship program ... This announcement follows a meeting held this summer ... In recent years, reporters have shed light on ...
(Date:8/30/2014)... York, New York (PRWEB) August 30, 2014 ... other incretin mimetic claims continue to move forward in ... statement issued by AstraZeneca PLC on July 31, 2014, ... been named in 409 product liability claims that allege ... Court documents indicate that many of these claims are ...
(Date:8/30/2014)... 30, 2014 In today’s world, a good ... get. Snoring and sleep apnea (a medical problem where the ... their bed partners of the rest they need to face ... population snores and 20 million people in the United States ... diagnosed and treated; and of those treated, many cannot tolerate ...
Breaking Medicine News(10 mins):Health News:Make Him Desire You Review Reveals Powerful Formula to Make a Man Emotionally Addicted 2Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 2Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 3Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 4Health News:Tennessee Hyperbaric Center Offering HBOT Scholarships to Veterans 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... Teens who eat less salt lower their long-term risk for high ... finding stems from a computerized projection of what would happen if ... salt from their daily consumption of common processed foods. "Reducing ... that we eat could mean that teenagers live many more years ...
... , SATURDAY, Nov. 13 (HealthDay News) -- People who ... increased risk themselves for the potentially deadly heart rhythm ... data from 4,421 participants in the long-term Framingham Heart ... start of the study. Between 1968 and 2007, 440 ...
... say that physicians might be drawing conclusions too soon ... whose bodies were for a day initially chilled into ... as therapeutic hypothermia, is one of the few medical ... stoppages, with brain recovery usually assessed three days after ...
... HealthDay Reporter , FRIDAY, Nov. 12 (HealthDay News) -- ... have made significant discoveries in the past year that might ... disease in its tracks. That,s some good ... in 1991 as a joint project between the International Diabetes ...
... Northwestern Memorial Hospital recently implanted a patient with two ... available for study in humans. VADs are designed to ... or both (BiVAD) at once. This is the first ... the left and right ventricles anywhere in North Americaa ...
... (HealthDay News) -- A minor gene variation may be associated with ... study has found. In a recent experiment, Martin Reuter, of ... with this variation in a gene known as COMT gave away ... people with another variation of the gene. The COMT gene ...
Cached Medicine News:Health News:Study Urges Teens to Cut Down on Salt 2Health News:Study suggests physicians wait longer for brain recovery after hypothermia Rx in cardiac arrest 2Health News:Study suggests physicians wait longer for brain recovery after hypothermia Rx in cardiac arrest 3Health News:Diabetes Research Made Significant Strides in Past Year 2Health News:Diabetes Research Made Significant Strides in Past Year 3Health News:Small assist device used in emergency case as twin, heart booster pumps for first time in US 2
(Date:8/30/2014)... , Aug. 30, 2014  Boston Scientific ... NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) clinical ... trial investigating vagus nerve stimulation (VNS) for the ... Ph.D., Professor of Therapeutics and Cardiology and Director ... National de la Sante et de la Recherche ...
(Date:8/30/2014)... , Aug. 30, 2014   Royal Philips  ... Affiniti, a new ultrasound system designed to ... demands of increasing patient volumes and cost pressures. Making ... 2014 in Barcelona this ... facing more patients with fewer resources deliver high quality ...
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire-iReach/ -- Market Research Report ... 2009-2019 is a professional and in-depth market survey ... industry . The report firstly reviews the basic ... application and manufacturing technology. The report then explores ... Scanner listing their product specification, capacity, Production value, ...
Breaking Medicine Technology:Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 2Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 3Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 4Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 2Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 3Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5
... Financial Guidance, DUBLIN, Calif., July 1 ... dedicated to the discovery, rapid,development and commercialization ... today commented on the preliminary efficacy,data from ... (decitabine) for,Injection to best supportive care (BSC) ...
... SOUTH EASTON, Mass., July 1 Pressure,BioSciences, Inc. ... scientists,from the New York University ("NYU") School of ... on advances they made in the,areas of breast ... The results were generated in studies using PBI,s ...
Cached Medicine Technology:SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes 2SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes 3SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes 4Pressure Cycling Technology (PCT) Results in a Higher Yield of Proteins and in the Extraction of Proteins Not Previously Identified in Cancer, Stroke, and IVF Studies 2Pressure Cycling Technology (PCT) Results in a Higher Yield of Proteins and in the Extraction of Proteins Not Previously Identified in Cancer, Stroke, and IVF Studies 3
The MULTI-LINK PIXEL Coronary Stent System was designed to address the challenges of small vessel treatment in patients with abrupt or threatened abrupt closure (ATC)....
FemoStop system is a femoral compression system for hemostasis management. It provides a comfortable and efficient "hands off method of compressing the femoral artery and vein after diagnostic and i...
... VHD was the first ... bleeding after diagnostic and ... procedures. It is a ... approved for immediate sheath ...
... VHD was the first ... bleeding after diagnostic and ... procedures. It is a ... approved for immediate sheath ...
Medicine Products: